

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida, Executive Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

### **Daiichi Sankyo Selects Research Partners for TaNeDS Collaborative Drug Discovery Project**

**Tokyo, Japan (November 10, 2015)**- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has selected research partners for its 2015 TaNeDS (**T**ake a **N**ew challenge for **D**rug di**S**covery) collaborative drug discovery project.

TaNeDS, which began in 2011 as part of Daiichi Sankyo's open innovation program, selects researchers from universities and public research centers in Japan, and Daiichi Sankyo will soon begin signing agreements with this year's selected parties to initiate collaborative research.

1. Total entries: 227

2. Selected parties: 20

3. Selections by entry type

Project type	Entries	Passed second selections	Final selections
<b>A. Daiichi Sankyo's Desired Research Themes</b> <sup>*1</sup>	<b>217</b>	<b>34</b>	<b>19</b>
a. Drug discovery target verification	112	9	8
b. Drug discovery target investigation	98	10	3
c. Drug discovery technology development/verification	60	12	6
d. Pharmaceutical technology	12	3	2
<b>B. Daiichi Sankyo RD Novare's Desired Research Themes</b> <sup>*2</sup>	<b>10</b>	<b>1</b>	<b>1</b>

<sup>\*1</sup> Type A contains 4 categories, thus entries with multiple categories are counted once for each category.

<sup>\*2</sup> Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare), Daiichi Sankyo's wholly owned subsidiary, joined TaNeDS to promote the development of novel technology platforms for drug discovery from 2013.

#### 4. Selections by research theme

Desired research themes	Entries	Passed second selections	Final selections
A. Daiichi Sankyo's Desired Research Themes			
• Oncology	128	8	4
• Other disorders	93	11	8
• Biologics	5	0	0
• DDS	21	4	1
• Pathological model/unique cell-based assays/vital imaging	8	1	0
• in silico models related to drug effect estimates/pathological clarification	10	0	0
• ADME (Drug Absorption, Distribution, Metabolism, Excretion)	10	2	2
• Drug safety	8	3	2
• Measuring technology related to biomarker	12	1	0
• Vaccines	6	1	0
• New synthetic technology	6	2	2
• Biomedicine safety technology	3	0	0
• Chemical compounds/drug analysis technology	3	1	0
B. RD Novare's Desired Research Themes	10	1	1
• Drug discovery and development technology platform research			
Total (Entries with multiple themes are counted once for each theme)	323	35	20

\*For more information about the TaNeDS program, please visit the Daiichi Sankyo corporate website (in Japanese): <http://www.daiichisankyo.co.jp/corporate/rd/taneds/>